HAYA Therapeutics

Switzerland
Malters, Lucerne, Switzerland

Company profile

HAYA Therapeutics company profile

HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome. The company leverages its proprietary platform to uncover new insights into disease-associated cell states and the long non-coding RNAs (lncRNAs) that control them. Its lead candidate, HTX-001, is being developed as a potential treatment for heart failure. In addition, the company is advancing a pipeline of precision therapies that target lncRNAs for cell-specific treatment of conditions affecting other tissues.

Business identity

Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2017-01-01, Year

Headquarters

Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
12
Total equity funding
$1.1B
Last funding
Grant / 2025-09-01
Last equity funding
Series A / $65M
Investors
19
Lead investors
8
Founders
2
Articles
82

Founders and investors

Founders

Daniel BlessingSamir Ounzain

Lead investors

Apollo Health VenturesBroadview VenturesEarlybird Venture CapitalEli LillyHumboldt FundInnosuisseSofinnova PartnersVenture Kick

Investors

Alexandria Venture InvestmentsApollo Health VenturesEli LillySchroders CapitalSofinnova Partners